REDX
PHARMA PLC
("Redx"
or the "Company")
Statement re Press
Report
Alderley Park, UK, 14 February 2024 Redx (AIM:REDX), the clinical-stage biotechnology company
focused on discovering and developing novel, small molecule,
targeted therapeutics for the treatment of fibrotic disease and
cancer notes the article published on the website of The Times on
13 February 2024 stating that the Company is "eyeing" a US listing.
Redx wishes to clarify that it is
not currently in any process relating to a listing in the US, nor
any other jurisdiction.
As previously stated, the Board
continues to consider all financing and
other strategic options to extend the cash runway in the best
interests of all shareholders.
|
For
further information, please contact:
|
|
|
|
|
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
|
|
|
|
|
|
|
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
|
Matt Davis/ Adam Dawes
|
|
|
|
|
|
|
|
WG
Partners LLP (Joint Broker)
|
T: +44 (0)203 705 9330
|
|
|
Claes Spång/ Satheesh Nadarajah/
David Wilson
|
|
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
T: +44 (0)207 886 2500
|
|
|
Rupert Dearden/ Freddy Crossley/
Emma Earl
|
|
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
|
Simon Conway/ Ciara
Martin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company's lead
fibrosis product candidate, the selective ROCK2 inhibitor,
zelasudil (RXC007), is in development for interstitial lung disease
and is undergoing a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a
GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is progressing towards the clinic with a Clinical
Trial Application (CTA) submitted during Q4 2023. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, being
developed as a targeted treatment for Wnt-ligand dependent cancers,
is expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.